<DOC>
	<DOCNO>NCT00791570</DOCNO>
	<brief_summary>The purpose study evaluate safety time progression HLA-A*2402 A*0201 restrict epitope peptide VEGFR1 VEGFR2 emulsify Montanide ISA 51 patient Neovascular Maculopathy , include Age Related Macular Degeneration</brief_summary>
	<brief_title>Anti-VEGFR Vaccine Therapy Treating Patients With Neovascular Maculopathy</brief_title>
	<detailed_description>VEGF receptor 1 2 essential target pathogenic angiogenesis , identify peptide derive receptor significantly induce effective tumor specific CTL response vitro vivo . According finding , trial , evaluate safety , immunological clinical response peptide . Patients vaccinate week 12 week . On vaccination day , VEGFR1 peptide ( 1mg ) VEGFR2 peptide ( 1mg ) mixed Montanide ISA 51 administer subcutaneous injection . In study , primary aim evaluate safety tolerability peptide vaccine . The second aim evaluate immunological clinical response vaccine therapy .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Neovascular Maculopathy include Age Related Macular Degeneration . Resistant PDT Anti VEGF therapy Patient disagree therapy . HLAA*2402 A*0201 Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) Breastfeeding Active uncontrolled infection Unhealed external wound Concurrent treatment steroid immunosuppressing agent Uncontrolled brain and/or intraspinal lesion ( ) Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>